Vaxcyte Dividend

Dividend criteria checks 0/6

Vaxcyte does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.9%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$3.70
Dividend yield forecast in 3Y	0%

Recent dividend updates

No updates

Recent updates

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Dec 27

We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely

Sep 12

Here's Why We're Not Too Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Situation

May 30

Vaxcyte completes enrollment in phase 2 portion of study of pneumonia vaccine candidate

Jul 12

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Feb 25

We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely

Nov 08

We're Interested To See How Vaxcyte (NASDAQ:PCVX) Uses Its Cash Hoard To Grow

Jul 26

We're Interested To See How Vaxcyte (NASDAQ:PCVX) Uses Its Cash Hoard To Grow

Apr 12

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if PCVX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PCVX's dividend payments have been increasing.

Dividend Yield vs Market

Vaxcyte Dividend Yield vs Market

How does PCVX dividend yield compare to the market?
Segment	Dividend Yield
Company (PCVX)	n/a
Market Bottom 25% (US)	1.6%
Market Top 25% (US)	4.8%
Industry Average (Biotechs)	2.9%
Analyst forecast in 3 Years (PCVX)	0%

Notable Dividend: Unable to evaluate PCVX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PCVX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate PCVX's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PCVX has not reported any payouts.

Vaxcyte Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

President & CFO notifies of intention to sell stock

Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024

President & CFO notifies of intention to sell stock

New major risk - Revenue and earnings growth

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

New major risk - Revenue and earnings growth

President & CFO notifies of intention to sell stock

Vaxcyte, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

President & CFO notifies of intention to sell stock

Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer

Price target increased by 7.8% to US$71.14

Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise

Co-Founder notifies of intention to sell stock

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Senior VP notifies of intention to sell stock

Vaxcyte, Inc. Announces the Publication of the Results from the VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in the Journal The Lancet Infectious Diseases

Vaxcyte, Inc. Appoints Jacks Lee to Board of Directors

President & CFO notifies of intention to sell stock

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

President & CFO notifies of intention to sell stock

Vaxcyte, Inc. Announces FDA Clearance of Investigational New Drug Application for Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

Co-Founder notifies of intention to sell stock

We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Situation

Vaxcyte, Inc. to Report Q4, 2022 Results on Feb 27, 2023

President exercised options to buy US$1.1m worth of stock.

Vaxcyte’S VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults

Executive VP & COO exercised options to buy US$5.1m worth of stock.

We Think Vaxcyte (NASDAQ:PCVX) Can Afford To Drive Business Growth

Vaxcyte, Inc. Announces Executive Changes, Effective January 1, 2023

Independent Director exercised options and sold US$131k worth of stock

High number of new directors

Price target increased to US$60.50

Independent Director exercised options and sold US$147k worth of stock

Price target increased to US$56.00

Vaxcyte, Inc. Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24 Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64

Co-Founder & VP of Research notifies of intention to sell stock

Vaxcyte, Inc. Announces Executive Appointments

Vaxcyte appoints new CBO, CMO

Co-Founder notifies of intention to sell stock

Co-Founder & VP of Research notifies of intention to sell stock

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older

Co-Founder notifies of intention to sell stock

Co-Founder & VP of Research notifies of intention to sell stock

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Insider notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

President & CFO notifies of intention to sell stock

Vaxcyte, Inc. Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-Of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of Vax-24 in Adults

Vaxcyte completes enrollment in phase 2 portion of study of pneumonia vaccine candidate

Executive VP & COO notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Co-Founder & VP of Research notifies of intention to sell stock

Insider notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

High number of new directors

Co-Founder notifies of intention to sell stock

Vaxcyte, Inc., Annual General Meeting, Jun 01, 2022

Co-Founder & VP of Research notifies of intention to sell stock

Vaxcyte, Inc. Announces Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in Adults

President & CFO notifies of intention to sell stock

Insider notifies of intention to sell stock

Chief Operating Officer notifies of intention to sell stock

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Vaxcyte, Inc. Announces the First Participants Dose in the Phase 1/2 Clinical Study of VAX-24

Vaxcyte, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease

Co-Founder & VP of Research exercised options and sold US$104k worth of stock

Co-Founder & VP of Research exercised options and sold US$96k worth of stock

Co-Founder & VP of Research notifies of intention to sell stock